Birch Biosciences

Birch Biosciences successfully scales its enzymatic recycling process, achieving commercialization beyond the pilot stage and securing major contracts based on its $80M in Letters of Intent. The AI-driven enzyme engineering platform allows for rapid expansion into new plastic types, establishing Birch as a leader in sustainable plastic recycling. This drives a Series B/C valuation of $100M+ (4x current $25M) within 2 years, with strong prospects for further growth.

Birch Biosciences successfully completes its pilot commercialization in 2026 and secures initial smaller-scale contracts. It continues to develop its enzyme platform but faces challenges in rapid scale-up and competition from other enzymatic recycling firms. The company raises a successful Series A/B round, reaching a valuation of $40M-$50M (1.6x-2x current $25M) within 2 years, reflecting steady progress but slower market penetration.

Birch Biosciences encounters significant technical hurdles in scaling its process beyond pilot, or faces intense competition from well-funded rivals like Carbios and Samsara Eco who achieve market dominance. Regulatory approvals prove more complex and costly than anticipated, leading to delays and increased capital burn. The company struggles to raise subsequent funding at a favorable valuation, resulting in a down round or limited growth, with common stock value decreasing by 80% to $5M.